NewsRelease
ResearchArticle Cites Cleanascite™ for Bead-based Antibody ArrayProteome Analysis of Human Bile
MONMOUTHJUNCTION, NJ,February22, 2017 -- Biotech Support Group reports on a recent researcharticle describing the simplicity and efficiency of their lipidclearance sample preparation technology for bile fluid.
Thecitation is:
Vesterhus,Mette, et al. "Novel serum and bile protein markers predictprimary sclerosing cholangitis disease severity and prognosis."Journalof Hepatology(2017).
http://dx.doi.org/10.1016/j.jhep.2017.01.019
Inbrief, the article’s authors aimed to identify novel proteinbiomarkers of disease severity and prognosis in primary sclerosingcholangitis (PSC). They analyzed bile samples using a bead-basedarray targeting 63 proteins. The article states “The sampleswere thawed and 100 μL of bile was added to 150 μL PBScontaining 0.1% Tween 20 and Protease Inhibitor Cocktail(Sigma-Aldrich, St. Louis, Missouri, USA), then centrifuged at 4 °Cfor 10 minutes at 14000 rpm. CleanAscite™ (100 μL, BiotechSupport Group, NJ, USA)…”. The authors identified novelbiliary and serum biomarkers of severity and prognosis in PSC.
“Thisreference shows the versatility of Cleanascite™to efficiently remove lipids from bile fluid, with a selectivityprofile suitable for proteome analysis using antibody-based arrays.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866